/ /

Advances

Topical inhibits sebum to control acneThe investigational sebum-inhibiting topical DRM01 had positive results in a phase 2b study, which paves the way for phase 3 trials planned for 2017.
Investigational topical promising underarm sweat treatmentResults indicate an investigational topical anticholinergic product in development for patients with primary axillary hyperhidrosis may offer patients an effective new treatment option if approved.
Patients demand access to investigational therapiesExpanded access or “compassionate use” programs allow patients to use investigational treatments, medical devices, or tests, before they have received FDA approval.
New hypertension drug gets FDA approvalThe first and only fixed-dose combination of a beta blocker beta blocker (BB) and angiotensin II receptor blocker (ARB) for hypertension will be available in the US in the second half of the year. FDA approved nebivolol and valsartan (Byvalson, Allergan) 5 mg/80 mg tablets in early June.
Gene tests predicts melanoma stagingA gene expression profile test rivals sentinel node biopsy in predicting distant metastasis in stage 1 and stage 2 melanoma, according to results from a new multicenter performance study.
FDA approves Zinbryta to treat multiple sclerosisFDA recently approved daclizumab (Zinbryta, Biogen and AbbVie), a once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (RMS).
Review examines psoriasis, smoking linkA recent paper sheds light on the relationship between smoking and psoriasis. Results offer a whole scenario related to the impact of smoking on psoriasis.
Study enrollment for prurigo nodular completeA phase 2/3 multi-center, randomized, double-blind, placebo-controlled, parallel, three-arm study looking at Nalbuphine ER for prurigo nodularis will evaluate safety and efficacy in 63 patients.
First 4-strain flu vaccine availableFDA recently approved the first 4-strain, cell culture-derived, inactivated seasonal flu vaccine available in the United States. Flucelvax Quadrivalent influenza vaccine (Seqirus) helps protect against the 2 influenza A viruses and two B viruses recommended by the World Health Organization (WHO) and the FDA for the current influenza season.
New diabetes drug enters competitive marketIn a major new entry in the diabetes market, FDA just approved linagliptin and metformin hydrochloride extended-release tablets (Jentadueto XR, Boehringer Ingelheim and Eli Lilly and Company) to treat type 2 diabetes.

Poll

View Results